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Abstract
Background: The detection of incidental findings (IF) in magnetic resonance imaging (MRI) studies is common and increases
as a function of age. Responsible handling of IF is required, with implications for the conduct of research and the provision
of good clinical care.
Aim: To investigate the prevalence and clinical significance of IF in a prospective cohort of healthy elderly volunteers who
underwent MRI of the torso as a baseline investigation for a phase I trial. We assessed the follow-up pathway with
consequent cost implications and impact on trial outcomes.
Methods: A total of 29 elderly healthy volunteers (mean age 67, range 61–77, 59% female) were eligible at screening and
underwent MRI for assessment of visceral and subcutaneous fat.
Results: IF were detected in 19 subjects (66%). Suspected IF of high and low clinical significance were found in 14% and
52% of participants, respectively. Follow up of IF was conducted in 18 individuals, confirming abnormalities in 13 subjects, 3
of whom were recommended for deferred clinical re-evaluation. The remaining 5 subjects had false positive IF based on
second line imaging tests. Costs of follow-up medical care were considerable.
Conclusion: MRI abnormalities are common in elderly individuals, as a result of age and non-diagnostic quality of research
scans. In the presence of IF in the context of clinical trials, immediate referrals and follow up assessments may be required to
rule out suspected pathology prior to exposing trial participants to investigational medicine products (IMP). Unanticipated
costs, ethical implication and the possible impact of IF on trial outcomes need to be taken into account when designing and
conducting trials with an IMP.
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Introduction
Phase I trials represent a necessary step in the drug development
process, in which preliminary data regarding the safety, tolerabil-
ity, pharmacokinetics and metabolism of novel investigational
medicinal products (IMP) are obtained from small groups of
healthy volunteers or patients [1].
Alongside traditional pharmacokinetic measures, that indeed
represent the primary endpoint of first-time in man (FTIM)
studies, initial evidence of pharmacodynamic (PD) effects is
increasingly being sought in early phase trials as a secondary
study endpoint [2]. While effects on PD endpoints in healthy
volunteers may not accurately predict the true clinical outcomes in
patients, they may provide initial indication as to whether novel
putative therapies are sufficiently promising to justify the conduct
of larger-scale longer-term clinical trials [3]. In addition, the use of
PD biomarkers in healthy volunteers can facilitate dose selection in
future efficacy trials in patients [4].
Imaging studies have gained increasing popularity in clinical
research as a reliable, reproducible and minimally invasive source
of biomarkers [5]. Different imaging modalities, including
magnetic resonance, ultrasound and positron emission tomogra-
phy (PET), have been variably employed to assess the bioactivity of
medicinal compounds across different disease areas, including
cardiovascular and metabolic medicine [6], neurosciences [7] and
oncology [8].
Among the imaging biomarkers tested in healthy individuals,
magnetic resonance imaging (MRI) holds several advantageous
properties, including accurate soft tissue contrast features, lack of
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ionizing radiation and the possibility of estimating physiological
parameters, such as blood flow, or to derive human body
composition by quantifying the distribution of adipose over
muscular tissue [9].
Because of these favorable properties, MRI has been used with
increasing frequency in clinical research and, as a result of the
increased number of subjects undergoing MRI scans, the detection
of incidental findings in otherwise healthy and asymptomatic
volunteers has become an ever more common occurrence.
A number of studies conducted in healthy volunteers have
reported a considerable proportion of unexpected radiological
findings of potential clinical significance following MRI investiga-
tion of various anatomical regions, mostly focusing on brain, head
& neck districts [10,11,12,13], where the prevalence of findings
requiring clinical follow-up or therapeutic intervention ranged
from 2 to 10% depending on the examined region.
A more recent study estimated a 13% prevalence of abnormal-
ities of moderate to high significance in whole body MRI scans,
reporting a steady increase in the risk of IFs associating with age
[14].
The clinical, ethical and emotional implications relating to the
detection of IFs represent a renowned challenge in clinical
research; most of the implications stemming from the report of
radiological abnormalities are inferred from observational studies
and may or may not inform an objective cost-benefit analysis for
screening of asymptomatic subjects.
Little is known about the impact of IFs in the conduct of phase I
trials. This lack of knowledge includes the financial consequences
that either sponsors or primary care providers may face from the
need of follow-up investigations subsequent to the discovery of
unexpected abnormalities.
In this study we report the rate and type of IFs on MRI scans of
the torso in a group of healthy elderly volunteers screened for an
IMP study and we address the resulting clinical, ethical and




The study population included for the present study is
composed of twenty-nine healthy volunteers who were considered
for a Phase I single-center study investigating the safety,
tolerability, pharmacokinetic and pharmacodynamics properties
of a novel compound being developed for the treatment of
metabolic disorders (ClinicalTrials.gov reference number
NCT00964340). The primary outcomes of the clinical trial are
published elsewhere (Libri et al., manuscript submitted).
As part of the screening process, all the volunteers underwent
medical history review and full clinical examination. Routine
blood and urine tests and an ECG were obtained to confirm
subject’s eligibility. The body mass index (BMI) ranged from 18
and 30 kg/m2. Subjects with any active medical diagnosis at
screening were excluded. Subjects were also ineligible if they had a
history of any chronic disease or any clinically significant illness
within 3 months of study entry that, in the opinion of the
investigators, could risk subject safety or interpretation of the
results.
The study was conducted at The National Institute for Health
Research (NIHR)-Wellcome Trust Imperial College Clinical
Research Facility (formerly known as McMichael-Welcome Trust
Clinical Research Facility) within Imperial College London, in
compliance with the Declaration of Helsinki and the International
Conference on Harmonisation (ICH) and Good Clinical Practice
(GCP) guidelines and after formal approval by the competent
Research Ethics Committee (reference number 09/H0505/96)
and the UK Medicines and Healthcare products Regulatory
Agency (MHRA). Written informed consent was obtained from
each subject prior to the performance of any study-specific
procedures.
Magnetic Resonance Imaging
Twenty-nine subjects underwent a Magnetic Resonance Imag-
ing (MRI) scan at study baseline to quantify intra-abdominal and
subcutaneous adipose tissue. Data were acquired on a Siemens 3T
Tim Trio MR scanner (Siemens Healthcare, Erlangen Germany)
with the 6 element phased array spine coil and two 4-element
phased array flexible torso coils using a 3D volume-interpolated
breath-hold examination (VIBE) [15] spoiled gradient echo
sequence acquiring two echo times (2.45 ms and 3.675 ms) in
order to capture water and fat with and without a 180u phase shift.
The imaging volume consisted of up to 5 contiguous axial 3D slabs
covering the top of the aortic arch to the femoral heads. Each slab
had a field of view of 450mm6267 mm, was acquired in a single
15-second end-expiration breath hold and contained 32 5-mm
slices with 1.461.4 mm2 resolution, using a 7 ms repetition time,
10u flip angle, 6/8 partial Fourier in both phase encoding
dimensions and a parallel imaging factor of 2. Complex-valued
data from each echo time were decomposed using the Dixon
technique into fat-only, water-only, in-phase, and opposed-phase
images [16].
Reporting, Disclosure and Follow-up of Incidental
Findings
During consent, every subject was informed about the chance of
unexpected findings being discovered during screening tests, in
accordance with study patient information sheet, which stated
explicitly the following: ‘‘there is a possibility that the tests
performed during the study will find a medical condition which
you did not know about. If this happens your research doctor will
discuss the result with you and will, with your permission, refer you
to your GP for further medical care’’.
Each participant consented to have their MRI scan reviewed by
a clinical radiologist to investigate the presence of unexpected
findings. A senior consultant radiologist, who interpreted the data
independently from the research team, reported the MRI scans.
Clinical correlation of each finding was discussed between
senior investigators from the medical team and the reporting
radiologist with the aim of facilitating the interpretation of the
scans and in order to ensure the provision of the most appropriate
follow up plans to the volunteers. Investigators organized follow-
up imaging tests after discussion with volunteers according to the
principles of good clinical practice.
For the purpose of data analysis, IFs were classified as being of
‘‘high’’ and ‘‘low’’ clinical significance according to their likelihood
to have an impact on subject’s health as described previously [14].
Briefly, abnormalities including indeterminate lesions in solid
organs and enlarged lymph nodes were classified as being of high
clinical significance. Abnormalities of low clinical significance were
those who did not require urgent follow up investigation or
treatment and included gallstones, diverticulosis and simple kidney
or liver cysts.
The estimated costs applying to each individual follow-up
examination agreed by the investigators were derived from the
local National Health Service (NHS) Trust Imaging Department
costing list applying to research studies. The costs of primary care
consultations were derived from the Unit Costs of Health and
Social Care Report 2009 [17].
Incidental MRI Findings in Elderly Volunteers
PLOS ONE | www.plosone.org 2 November 2012 | Volume 7 | Issue 11 | e49814
Data Collection and Analysis
Data were collected and analyzed using Microsoft Excel 2010
Version 14.0 (Microsoft Corporation, Washington, USA) imple-
mented with the XLSTAT add-in statistical package.
Results
Twenty-nine healthy elderly subjects whose clinical character-
istics at screening are summarized in Table 1, were included in
our analysis. The study participants were mostly female (n = 17,
59%) with a mean age of 67.1 years (range 61–77).
While body MRI scan at baseline revealed one or more
abnormalities in 19 subjects (66%), which were considered to be of
high and low clinical significance in 4 (14%) and 15 (52%) subjects,
respectively. The most commonly affected region was the
gastrointestinal tract (57%). The most frequently reported
abnormality was the presence of solitary cystic liver lesions in 7
subjects, comprising 30% of all the abnormalities detected. The
prevalence of IFs in our prospectively enrolled cohort, categorized
by site and degree of clinical significance, are described in Table 2
and in Figure 1.
Out of the 19 subjects with at least one MRI abnormality, 18
subjects underwent follow-up imaging investigations within 2
weeks from the referral. The remaining 1 subject did not require
follow up investigation as a definitive diagnosis of gallstones was
made on the original MRI scan. The most frequently performed
diagnostic test was abdominal ultrasound scan (US) in 8 cases.
In 10 of the 18 subjects referred for follow up assessment (56%),
IFs were confirmed (e.g. kidney and liver cysts, colon diverticulosis,
prostate enlargement) although they were not considered to
influence the subject’s health status or trial eligibility and did not
require further investigation. In 3 subjects (16%), follow-up scans
confirmed an abnormality requiring intervention or long term
follow-up: one case of liver cyst with complex echogenic structure
and a second subject with multiple thyroid nodules identified on
neck US were recommended to have deferred imaging re-
evaluation. A third patient with an incidental breast nodule with
equivocal mammographic and US features was recommended to
have a core biopsy. This patient withdrew consent and was
referred to her GP to allow for complete diagnostic characteriza-
tion and further medical care. After withdrawal of consent, the
subject had a core biopsy of her breast lesion performed elsewhere
and histopathological examination of the specimen was consistent
with fibroadenoma, for which conservative management was
recommended. In the remaining 5 individuals (28%) the follow-up
scan was negative for the abnormality specified in the MRI scan,
confirming a false positive reading in the first instance.
The diagnostic modality type, costs and clinical outcome
emerging from the follow-up investigations arranged for the
subjects in whom incidental MRI findings were identified are
summarized in Table 3. The global costs emerging from the
investigation of IFs amount to £ 7,775.00, implying an increase of
£ 268.00 in the clinical trial budget per individual patient
screened. The mean individual cost for a second-line imaging test
was £ 433.00 (95% CI 284–582), ranging from £ 255.00 to £
1,145.00 depending on the diagnostic modality utilized. The costs
generated from the 3 cases for which deferred follow up of IFs was
recommended amounted to £ 835.00. Two subjects were referred
to their GPs at the end of study for longer-term primary care,
whereas the subject with an incidental breast nodule required
further in-hospital diagnostic workup as illustrated in Table 3.
The cost per GP consultation was estimated based on an average
12 minute consultation [17]. Representative images from the
original MRI scans and from follow-up radiological investigations
are shown in Figure 2.
Discussion
IFs discovered during research imaging are defined as findings
with potential health or reproductive importance whose discovery
is unrelated to the purpose and beyond the aims of the study [18].
To date, no general consensus has been reached on how they
should be disclosed to subjects or handled [19]. The clear concern
is how to pursue further investigations without unduly alarming
the participant. The management plan is often devised case by
case by the investigators [20].
In the context of interventional studies, however, the implica-
tions of IFs are even more complex than in observational research,
as even abnormalities with minimal impact on participants’ health
may still influence the process of informed consent, recruitment
and safety follow-up offered to trial participants. In particular, it is
an ethical requirement for trial information sheets to reflect the
disclosure policy that researchers would have to adopt if IFs are
found [21]. In addition, in the specific area of IMP studies, where
individuals may be challenged with potentially toxic new chemical
entities, IFs may influence the conduct of the trial, prompting
investigators to consider the withdrawal of subjects with abnor-
malities requiring urgent follow up or whose presence may put
participants’ safety at risk if included in the study.
In this paper we report that 66% of the healthy elderly
volunteers considered for a Phase I IMP study were found to have
IF on baseline MRI scans; a proportion that is twice that
previously estimated [14]. This is perhaps not surprising consid-
ering the more advanced age of our population compared to
previous studies [14]. Nonetheless it is pertinent to the fact that
elderly individuals are increasingly recruited into Phase I IMP
studies, to fully appreciate age-related variations in the pharma-
cokinetic profile of the investigational drug under testing [22], or
to infer preliminary pharmacokinetic/pharmacodynamic relation-
ships in a subject sample as similar as possible to the foreseen
target patient population [23].
It is accepted that the overall prevalence of disease in elderly
individuals, even in the absence of clinical symptoms or signs, is
higher as a direct consequence of aging [24]. For this reason, the
presence of stringent, pre-defined eligibility criteria allows for the
detection of clinically significant abnormalities at screening, having
the dual aim of avoiding the exposure of subjects with medical
Table 1. Subjects demographics at screening.
Characteristic N=29
Age (years) Mean (range) 67.1 (61–77)
SD 64.1
Sex Female 17 (59%)
Male 12 (41%)
Ethnicity Asian 2 (7%)
Black 2 (7%)
White 25 (86%)
BMI (Kg/m2) Mean 25.6
SD ±2.3
Systolic Blood Pressure (mmHg) Mean 128.1
SD 615.3
doi:10.1371/journal.pone.0049814.t001
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conditions to potential harm as well as to protect trial results from
confounding factors in assessing the safety of the IMP [25].
Our results show that despite meeting all the entry criteria, 18/
29 of the considered subjects demonstrated suspected MRI
abnormalities at screening that, in the opinion of the reporting
radiologist, required appropriate follow up diagnostic assessment
to rule out the possibility that they reflected silent, previously
undetected pathologies. The above figures are in line with those
described by a larger study of 1192 asymptomatic individuals with
a median age of 54 years, in whom 86% of the whole body
computer tomography scans reported at least one abnormal
finding with further diagnostic evaluation being warranted in 43%
[26].
Table 2. The prevalence of incidental findings in elderly healthy volunteers, with categorization of the identified abnormalities by
anatomical site and level of clinical significance.
Abnormality




High clinical significance 4 (14%) 8 (35%)
Multiple liver lesions 2 (9.0%)
Focal liver lesion 1 (4.3%)
Breast lump (single/multiple) 2 (9.0%)
Lung nodules 1 (4.3%)
Mesenteric lymphadenopathy 1 (4.3%)
Thyroid nodule 1 (4.3%)
Low clinical significance 15 (52%) 15 (65%)
Solitary liver cystic lesion 7 (30.0%)
Diverticulosis 2 (9.0%)
Solitary kidney cystic lesion 3 (13.1%)
Prostate enlargement 1 (4.3%)
Gallstones 1 (4.3%)
Rotator cuff cyst 1 (4.3%)
No abnormalities detected 10 (34%)
doi:10.1371/journal.pone.0049814.t002
Figure 1. Anatomical site distribution of the incidental findings.
doi:10.1371/journal.pone.0049814.g001
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Interestingly, in 72% of the individuals who had a second line
diagnostic test, abnormalities were not considered to be of clinical
concern in 56% of the subjects, whereas they were of potentially
high clinical significance in 16% of the subjects and justified a
longer term follow-up including imaging re-evaluation and, in one
case, percutaneous biopsy.
The increased sensitivity of whole body MRI in detecting
morphological changes with possible pathological significance, in
conjunction with the higher prevalence of IF seen in elderly
individuals increases the importance of independent review of
research scans by senior radiologists in order to optimize the
management and follow-up pathway of IF as early as possible [27].
On the other hand, the risk of false positives, which in this study
accounted for 28% of the reported lesions, needs to be taken into
account when tests of limited diagnostic quality are used(13).
In our study the MRI sequences were designed for delineating
anatomical structures and to be acquired within a short breath-
hold, using T1-weighted images. Despite being entirely appropri-
ate for the research need, the use of T1-weighted Dixon VIBE
sequence had implications with regards to the diagnostic
interpretation of the images and did pose some small issues with
flow and ghosting artifact in some cases. It is debatable that with
the addition of some T2 weighted images, radiological character-
ization would have been aided and may have reduced the
percentage of false positives and therefore the need for second line
diagnostic tests.
There are in fact differing views as to whether T2 weighted
MRI sequences should be obtained in all subjects or reserved as an
additional diagnostic step in those with IF evident on T1 weighted
images.
In our study, optimal diagnostic characterization of IF was
achieved only after the integrated use of multiple imaging
techniques including CT or ultrasound, suggesting that the
addition of extra MRI sequences of diagnostic quality may not
have facilitated the diagnosis. The characterization of IFs is in fact
inherently difficult and poorly reproducible in asymptomatic
subjects, suggesting that the T1 MRI technique is only partially
contributing to the false positive interpretation rates we found.
The question then arises whether performing additional
diagnostic tests that are not specifically meeting the research aims
should always be included in study protocols.
Since there is no clear evidence that the follow up of
asymptomatic IFs consistently leads to the requirement of referral
for further specialist advice and/or the initiation of treatment, the
emerging costs arising from the diagnostic procedures involved





investigation Cost (£) Clinical outcome Management Plan Cost (£)
Lung nodules CT thorax 255.00 NAD/NFA
Single liver
cystic lesion
US abdomen 56345.00 Benign cyst (4 subjects)/NFA
No lesion identified (1 subject)
Multiple liver
lesions










US abdomen & renal
tract
26345.00 Benign cysts (Bosniak type I, 1
subject)/NFA
Benign kidney cyst
(Bosniak type I), no liver
lesion found (1 subject)/NFA
Single kidney
cystic lesion
US renal tract 345.00 Benign cyst (Bosniak type I)/NFA
Focal liver lesion US abdomen 345.00 Fatty deposition/NFA
Breast lump Bilateral Mammogram
& US breast
261,145.00 Indeterminate lesion in mammogram,
no lesion in US (1 subject)/NFA
Likely fibroadenoma (1 subject),
biopsy suggested.














CT abdomen & pelvis 255.00 Inflammatory changes/NFA
Imaging Costs 6,940.00 Follow-up Costs 835.00
Total Costs 7,775.00
Abbreviations: NAD=No abnormality detected, NFA=No further action recommended.
doi:10.1371/journal.pone.0049814.t003
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makes the process of an active search of pathology a point of great
controversy [28].
Our data contribute to this controversy by showing that despite
implementing an aggressive follow up policy in our trial, no
definitive diagnoses of clinical significant pathology could be made
in any of the subjects with IFs. However, this conclusion could be
drawn at the cost of considerable anxiety to trial participants,
which in most cases was unnecessary given the non-clinical
significance of IFs in our subjects. As a result, in a context where
IFs are highly prevalent but most often not impacting on subjects’
health status, clinical judgment should be used to inform subjects
and implement a responsible and cost-effective management plan
(13, 27). In such a delicate context, clinicians should pay adequate
attention to protect patient’s autonomy by defending their right
not to know what was found on research imaging, should this
represent the subject’s preference. Regardless of the disclosure
policy stated on the trial consent form, sufficient time should be
spent during the initial consultation to understand the volunteer’s
anticipated preferences in order to facilitate communication and
management plans in case IFs are discovered.
In our analysis, we focused our attention on considering the
impact of incidental radiological findings on outcomes that are
relevant to the conduction of the trial including the eligibility of
the screened subjects, dropout rates and the cost implications
relating to the follow-up examinations.
In the context of IMP trials, IFs need to be followed up in order
to determine their possible clinical significance prior to proceeding
with the administration of the IMP. In principle, investigators may
be prompted to exclude subjects whose imaging findings cannot be
diagnostically characterized, but this would generate a detrimental
effect on recruitment and subsequent cost implications to primary
care providers. On the other hand, to maintain prospective
participants on an IMP trial IFs should be followed up in the
interest of subject’s safety and the costs of the required follow-up
tests should be covered by the sponsor (as in the present study) and
the planned IMP dosing date may be postponed to allow for the
completion of the second line diagnostic assessment.
In our experience, the referral process was completed within 1
week from the reporting of the original MRI scan, resulting in a
minimal disruption of trial related procedures. However, the fact
that this trial was carried out in a dedicated clinical research
facility with extensive experience in early phase trials and a direct
link to the NHS infrastructures may have contributed to a relative
containment of the delays that may not necessarily be replicated in
other contexts.
As reported in Table 3, the cost implications stemming from the
need to come to a definite diagnostic conclusion were substantial
and led to an overall increase in the trial costs. Furthermore, in
one case, the fortuitous discovery of a breast nodule requiring
further diagnostic characterization induced a participant to
Figure 2. Examples of two subjects with incidental findings from research MRI scans and their associated follow up investigations.
Panel A shows an in-phase axial Dixon VIBE MR image displaying a lesion (white arrow) in the right breast classified as being of high clinical
significance. Panel B shows the clinical mammogram image that correlate to A. In Panel C a cystic lesion arising from the upper pole of the right
kidney (white arrow) is seen on a water-only Dixon VIBE MR image and classified as being of low clinical significance. This was further diagnosed as a
cortical kidney cyst (Bosniak Type I) on follow up ultrasound scan (Panel D).
doi:10.1371/journal.pone.0049814.g002
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withdraw from the study to allow for a more accurate clinical
investigation.
The retrospective analysis of a single clinical trial population
with a relatively limited sample size should be acknowledged as a
potential limitation to the present study. However, the baseline
characteristics as well as the eligibility criteria applied to select our
prospectively enrolled cohort are those commonly seen in Phase I
trials in elderly volunteers [29]. It is conceivable that the policy of
our center in determining disclosure and follow-up plan of IFs may
not be shared by other research facilities. However, such degree of
variability among researchers is acknowledged, since no univer-
sally agreed guidelines are in place to guide investigators in the
disclosure and management of IFs [30]. It should also be
acknowledged that our financial analysis is based on fees applying
to the National Health Service in the United Kingdom, which may
be dissimilar in other contexts. However, when compared to
recently published data, the costs generated by the investigation of
IFs we reported do not significantly differ [31,32].
Despite the acknowledged limitations, our data suggest that the
majority of healthy elderly volunteers may be anticipated to have
unexpected IFs in MRI scans. In one case the discovery of an IF
led to withdrawal of consent. In two other cases long-term follow
up was recommended.
The elevated prevalence of abnormalities of low clinical
significance and the relatively high rate of false positive readings
highlights the importance of accurate reporting of MRI to prevent
unnecessary worry of research participants, reduce follow-up costs
and optimize management plans. Discrimination between false
positives and asymptomatic pathological findings is inherently
difficult costly and time-consuming follow-ups. Clinical judgment
in harmony with volunteers’ preference should guide follow-up
plans to safeguard research participants’ autonomy and ensure
correct implementation of ethically approved protocols. The
ethical, financial and practical implications originating from our
findings should be acknowledged in clinical trial design and
management.
Acknowledgments
The authors would like to acknowledge Prof. Paul M. Matthews, Head of
Division of Brain Sciences, Department of Medicine, Imperial College
London, for his support and his insightful comments on the manuscript.
Author Contributions
Conceived and designed the experiments: DJP VL MRW EWJ. Analyzed
the data: DJP VL AE MT. Contributed reagents/materials/analysis tools:
DJP EWJ MT AE. Wrote the paper: DJP CS MRW MT VL.
References
1. Macaluso M, Krams M, Preskorn SH (2011) Phase I trials: from traditional to
newer approaches. Part I. J Psychiatr Pract 17: 200–203.
2. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, et al. (2010)
Guidelines for the development and incorporation of biomarker studies in early
clinical trials of novel agents. Clin Cancer Res 16: 1745–1755.
3. Frank R, Hargreaves R (2003) Clinical biomarkers in drug discovery and
development. Nat Rev Drug Discov 2: 566–580.
4. Merlo Pich E (2011) Understanding pharmacology in humans: Phase I and
Phase II (data generation). Curr Opin Pharmacol 11: 557–562.
5. Pien HH, Fischman AJ, Thrall JH, Sorensen AG (2005) Using imaging
biomarkers to accelerate drug development and clinical trials. Drug Discov
Today 10: 259–266.
6. Rajaram V, Pandhya S, Patel S, Meyer PM, Goldin M, et al. (2004) Role of
surrogate markers in assessing patients with diabetes mellitus and the metabolic
syndrome and in evaluating lipid-lowering therapy. Am J Cardiol 93: 32C–48C.
7. Filippi M, Agosta F (2010) Imaging biomarkers in multiple sclerosis. J Magn
Reson Imaging 31: 770–788.
8. Sharma R, Aboagye E (2011) Development of radiotracers for oncology–the
interface with pharmacology. Br J Pharmacol 163: 1565–1585.
9. Ross R, Goodpaster B, Kelley D, Boada F (2000) Magnetic resonance imaging
in human body composition research. From quantitative to qualitative tissue
measurement. Ann N Y Acad Sci 904: 12–17.
10. Reneman L, de Win MM, Booij J, van den Brink W, den Heeten GJ, et al.
(2012) Incidental Head and Neck Findings on MRI in Young Healthy
Volunteers: Prevalence and Clinical Implications. AJNR Am J Neuroradiol.
11. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, et al. (2007)
Incidental findings on brain MRI in the general population. N Engl J Med 357:
1821–1828.
12. Katzman GL, Dagher AP, Patronas NJ (1999) Incidental findings on brain
magnetic resonance imaging from 1000 asymptomatic volunteers. JAMA 282:
36–39.
13. Hartwigsen G, Siebner HR, Deuschl G, Jansen O, Ulmer S (2010) Incidental
findings are frequent in young healthy individuals undergoing magnetic
resonance imaging in brain research imaging studies: a prospective single-center
study. J Comput Assist Tomogr 34: 596–600.
14. Morin SH, Cobbold JF, Lim AK, Eliahoo J, Thomas EL, et al. (2009) Incidental
findings in healthy control research subjects using whole-body MRI. Eur J Radiol
72: 529–533.
15. Rofsky NM, Lee VS, Laub G, Pollack MA, Krinsky GA, et al. (1999) Abdominal
MR imaging with a volumetric interpolated breath-hold examination. Radiology
212: 876–884.
16. Glover GH (1991) Multipoint Dixon technique for water and fat proton and
susceptibility imaging. J Magn Reson Imaging 1: 521–530.
17. Curtis L (2009) Unit Costs of Health and Social Care 2009. Canterbury:
University of Kent.
18. Wolf SM, Lawrenz FP, Nelson CA, Kahn JP, Cho MK, et al. (2008) Managing
incidental findings in human subjects research: analysis and recommendations.
J Law Med Ethics 36: 219–248, 211.
19. Booth TC, Jackson A, Wardlaw JM, Taylor SA, Waldman AD (2010) Incidental
findings found in ‘‘healthy’’ volunteers during imaging performed for research:
current legal and ethical implications. Br J Radiol 83: 456–465.
20. Ross K (2005) When volunteers are not healthy. EMBO Rep 6: 1116–1119.
21. CIOMS (2002) International ethical guidelines for biomedical research involving
human subjects. Geneva: Council for International Organizations of Medical
Sciences.
22. Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and
pharmacodynamics: basic principles and practical applications. Br J Clin
Pharmacol 57: 6–14.
23. Grundman M, Farlow M, Peavy G, Kim HT, Capparelli E, et al. (2002) A phase
I study of AIT-082 in healthy elderly volunteers. J Mol Neurosci 18: 283–293.
24. Fries JF (1988) Aging, illness, and health policy: implications of the compression
of morbidity. Perspect Biol Med 31: 407–428.
25. Pasqualetti G, Gori G, Blandizzi C, Del Tacca M (2010) Healthy volunteers and
early phases of clinical experimentation. Eur J Clin Pharmacol 66: 647–653.
26. Furtado CD, Aguirre DA, Sirlin CB, Dang D, Stamato SK, et al. (2005) Whole-
body CT screening: spectrum of findings and recommendations in 1192
patients. Radiology 237: 385–394.
27. Pickard JD, Gillard JH (2005) Guidelines reduce the risk of brain-scan shock.
Nature 435: 17.
28. Royal JM, Peterson BS (2008) The risks and benefits of searching for incidental
findings in MRI research scans. J Law Med Ethics 36: 305–314, 212.
29. Nunes T, Rocha JF, Vaz-da-Silva M, Falcao A, Almeida L, et al. (2011)
Pharmacokinetics and tolerability of etamicastat following single and repeated
administration in elderly versus young healthy male subjects: an open-label,
single-center, parallel-group study. Clin Ther 33: 776–791.
30. Booth TC, Waldman AD, Wardlaw JM, Taylor SA, Jackson A (2012)
Management of incidental findings during imaging research in ‘‘healthy’’
volunteers: current UK practice. Br J Radiol 85: 11–21.
31. Ding A, Eisenberg JD, Pandharipande PV (2011) The economic burden of
incidentally detected findings. Radiol Clin North Am 49: 257–265.
32. Tootell A, Vinjamuri S, Elias M, Hogg P (2012) Clinical evaluation of the
computed tomography attenuation correction map for myocardial perfusion
imaging: the potential for incidental pathology detection. Nucl Med Commun
33: 1122–1126.
Incidental MRI Findings in Elderly Volunteers
PLOS ONE | www.plosone.org 7 November 2012 | Volume 7 | Issue 11 | e49814
